ECRAID is an initiative from PREPARE and COMBACTE and involves key partners from both consortia. The clinicial research networks that are going to form ECRAID are currently functioning as the clinical research base for the studies in PREPARE, COMBACTE, RECOVER and many more other studies.
One of these studies is The Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP). As an adaptive platform, REMAP-CAP is designed to adapt in the event of a pandemic, increasing the likelihood of patients receiving an effective treatment. Since the COVID-19 outbreak, the platform has extended its domains to investigate new treatments specifically for COVID-19 patients on the ICU and the ward.
With the ability to improve the design according to new insights and already having the clinical trial infrastructure in place to implement these insights swiftly, various interventions can be tested simultaneously within multiple therapeutic domains. This video shows the uniqueness, smart, and easy-to-handle design of this trial.